All Videos

Michael Lewitt, MD, discusses a case involving a 55-year-old man with psoriasis (PsO) and psoriatic arthritis (PsA), highlighting challenges such as treatment for sensitive areas like the palms, soles, and scalp, mild morning stiffness, and the patient’s dissatisfaction with prior topical treatments; the discussion includes systemic and topical steroid use, concerns about TNF inhibitors, the effectiveness of phototherapy on limited areas, and the potential adverse events associated with the apremilast standard dose regimen, with phototherapy considered as a rescue option for flares.

Michael Lewitt, MD, provides an overview of Case-Based Roundtable and introduces a case involving a patient with a 10-year history of plaque psoriasis (PsO) in sensitive areas, discussing the significant impact on quality of life, the patient’s aversion to needles as a new mom, and the exploration of biologic therapies as a treatment option.

Panelists discuss how a multidisciplinary approach involving dermatologists, surgeons, radiation oncologists, and medical oncologists is crucial for optimal decision-making and management of complex basal cell carcinoma (BCC) cases, ensuring comprehensive care and improved patient outcomes.

Panelists discuss the current landscape of topical treatments for atopic dermatitis, focusing on the evolution of nonsteroidal options over the past decade, and explain the mechanism of action of PDE4 inhibitors in specifically targeting inflammatory pathways associated with the condition.

Monica Boen, MD, discusses how implementing proven photodynamic therapy techniques and adhering to best practices can significantly improve treatment outcomes and patient satisfaction.

Monica Boen, MD, discusses how optimizing photodynamic therapy protocols and streamlining patient scheduling can enhance treatment efficiency and maintain steady patient flow in clinical settings.

Panelists discuss how advanced basal cell carcinoma (BCC) presents unique treatment challenges and examine recent developments that show promise for improving outcomes in patients with this aggressive form of skin cancer.

Monica Boen, MD, discusses how analyzing seasonal trends in photodynamic therapy usage and effectiveness can improve treatment planning and patient outcomes.

Delve into the complexities of generalized pustular psoriasis (GPP), a rare and life-threatening skin condition, and explore how the monoclonal antibody spesolimab is being investigated to prevent severe, unpredictable flares.

Ted Lain, MD, MBA, FAAD, discusses how selecting the optimal photodynamic therapy approach involves considering factors such as the specific disease characteristics, patient conditions, available photosensitizers, light sources, and potential combinations with other treatments to maximize efficacy and minimize adverse effects.

Ted Lain, MD, MBA, FAAD, discusses how combining photodynamic therapy with other treatment modalities can potentially enhance therapeutic outcomes, reduce adverse effects, and overcome resistance mechanisms in various diseases, particularly in cancer treatment.

Explore the groundbreaking findings from the Effisayil 2 trial on the efficacy and safety of subcutaneous spesolimab in preventing flares of generalized pustular psoriasis.

Ted Lain, MD, MBA, FAAD, discusses how a combination approach in photodynamic therapy integrates multiple treatment modalities or agents to enhance therapeutic efficacy and overcome limitations of standalone photodynamic treatments for various cancers and other diseases.

Anthony M. Rossi, MD, shares their perspective on the future evolution of photodynamic therapy (PDT) in dermatology practices and discusses emerging data or studies that will be crucial for dermatologists to stay informed about.

Anthony M. Rossi, MD, highlights a successful case of photodynamic therapy (PDT), provides background on the patient’s outcome, and explains how increased use of PDT can enhance patient satisfaction and improve practice outcomes.

Anthony M. Rossi, MD, discusses common barriers to implementing photodynamic therapy (PDT), and provides solutions to specific challenges in the treatment setting.

E. James Song, MD, FAAD, provides key takeaways on the treatment of patients with plaque psoriasis, highlighting ways to define treatment success and the effect of adverse events on long-term treatment choices.

A dermatologist shares perspectives on patient-specific factors that impact treatment decisions in plaque psoriasis.

Panelists discuss how treatment cycling strategies and optimal use of ruxolitinib can enhance the management of vitiligo, providing key takeaways for clinical practice.

Panelists discuss how research in pediatric psoriasis management needs more attention on long-term safety, treatment efficacy, and the psychosocial impact of the disease on young patients.

An expert on plaque psoriasis provides an overview of systemic therapy options and provides clinical insights on patient monitoring practices and best courses of action when treatment response isn’t sustained.

E. James Song, MD, FAAD, presents a case of a 58-year-old patient with location-specific mild-to-moderate plaque psoriasis.

Panelists discuss how to optimize plaque psoriasis treatment in a 32-year-old man, with a specific focus on addressing genital plaques to enhance patient comfort and improve overall treatment outcomes.

Panelists discuss how to develop tailored treatment approaches for a 34-year-old African American woman with plaque psoriasis, focusing on exploring nonsystemic options that consider her specific demographic and clinical profile.

Panelists discuss how to effectively manage plaque psoriasis in a 55-year-old man by evaluating and potentially combining topical treatments with systemic therapies for optimal disease control.

Panelists discuss how their clinical experiences with topical ruxolitinib are shaping new treatment paradigms for vitiligo, while also addressing challenges related to medication access.

Panelists discuss how the two approved PDE4 inhibitors for pediatric plaque psoriasis differ in their systemic treatments, highlighting key differences in efficacy, safety profiles, and patient considerations for optimal use.

Panelists discuss how novel treatment mechanisms, efficacy assessments, and improved patient engagement strategies are shaping the evolving landscape of vitiligo management.

Panelists discuss how phosphodiesterase-4 (PDE4) inhibitors, with their ability to modulate inflammatory pathways, hold promise as therapeutic targets for immune-mediated diseases like pediatric plaque psoriasis, offering unique benefits by potentially reducing inflammation with a favorable safety profile for pediatric patients.

A dermatologist provides clinical insights on navigating dose escalation and insurance barriers for patients receiving treatment for plaque psoriasis.